奥马珠单抗治疗慢性自发性荨麻疹的研究进展

中图分类号：R758.24 文献标志码：A 文章编号：1001-5779（2025）06-0586-06

DOI：10.3969/j. issn. 1001-5779.2025.06.013

Research progressonomalizumabinthetreatmentof chronicspontaneousurticaria

ZHANG Xiang-yin 1 ，HUANG Xin-yuan’，ZHOU Yao-hui1，LAN Yue-long'，YOU Cong²，ZENG Zhao-lin² （1.The First Clinical Medical School of Gannan Medical University；2.Departmentof Dermatology， TheFirst Affiliated Hospital.ofGannan Medical University，Ganzhou，Jiangxi ）

Abstract：Chronic spontaneous urticaria（CSU） is acommon dermatological condition characterized bythe recurenceof pruritic wheals for morethan six weeks withoutan identifiable trigger，withor withoutangioedema.Thepersistenceof these symptomscan severelyimpact patients'qualityof lifeandmentalhealth.Although traditional medical research has madesignificant advancements，the treatmentof CSUremains challenging，with the second-generation H1 receptor antagonistsrecommendedbythe international EAACI/GA²LEN/EuroGuiDerm/APAAACIguideline for thedefinition， classification，diagnosis，andmanagementofurticariafailing toachievesatisfactoryresultsforsomepatients.Currntly， with the acelerated developmentof biologics andsmall moleculedrugs，omalizumab has been approved for the treatmentof CSU，ofering great prospects forpatientswith refractory CSU.This articlereviews the efficacy，safetyand predictivefactorsrelatedtotheeffectsofomalizumabinthetreatmentofCSU，aiming toprovideatheoreticalbasis for more personalized treatment plans forpatientswith CSU.

Keywords：Omalizumab；Chronicurticaria；Prognosis；Predictivefactors

慢性自发性荨麻疹（Chronic spontaneousurticaria，CSU）是一种常见的皮肤病，其特征为瘙痒性风团反复出现持续6周以上，可能伴有血管性水肿。（剩余13165字）